Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation

Advances in Anatomic Pathology

Volumn 9, Issue 1, 2002, Pages 24-36

  Brat, Daniel J ^a   Castellano Sanchez, Amilcar ^a   Kaur, Balveen ^b   Van Meir, Erwin G ^b  

^a EMORY UNIVERSITY HOSPITAL   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Astrocytoma; Genetics; Glioblastoma multiforme

Indexed keywords

ADULT; BRAIN TUMOR; DISEASE COURSE; GENETICS; GLIOBLASTOMA; HUMAN; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; REVIEW; VASCULARIZATION;

ADULT; BRAIN NEOPLASMS; DISEASE PROGRESSION; GLIOBLASTOMA; HUMAN; MIDDLE AGE; NEOVASCULARIZATION, PATHOLOGIC; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0036134029     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/00125480-200201000-00004     Document Type: Review

References (96)

1. Kleihuis P, Cavenee WK. Pathology and genetics of tumors of the nervous system. 2nd ed. Lyon: International Agency for Research, 2000.
2. Burger PC, Scheithauer BW. Tumors of the central nervous system. Atlas of tumor pathology. 3rd series, fascicle 10. Washington, DC: Armed Forces Institute of Pathology, 1994.
3. Brat DJ, Burger PC. Cerebral pilocytic astrocytoma: distinction from infiltrating "fibrillary" astrocytoma. Pathol Case Rev 1998;3:1-6.
4. Giannini C, Scheithauer BW, Burger PC, et al. Pleomorphic xanthoastrocytoma (pxa): what do we really know about it? Cancer 1999;85:2033-45. (Pubitemid 29202780)
5. Hirose T, Scheithauer BW, Lopes MB, et al. Tuber and subependymal giant cell astrocytoma associated with tuberous sclerosis: an immunohistochemical, ultrastructural, and immunoelectron and microscopic study. Acta Neuropathol (Berl) 1995;90:387-99.
6. Burger PC, Nelson JS, Boyko OB. Diagnostic synergy in radiology and surgical neuropathology: radiographic findings of specific pathologic entities. Arch Pathol Lab Med 1998;122:620-32. (Pubitemid 28334629)
7. Cavenee WK, Furnari FB, Nagane M, et al. Diffusely infiltrating astrocytomas. In: Kleihuis P, Cavenee WK, eds. Pathology and genetics of tumors of the nervous system. 2nd ed. Lyon: International Agency for Research, 2000;10-21.
8. Burger PC, Scheithauer BW, Vogel FS: Surgical pathology of the nervous system and its coverings. 3rd ed. New York, Churchill Livingstone, 1991.
9. Daumas-Duport C, Scheithauer BW, O'Fallon J, et al. Grading of astrocytomas. A simple and reproducible method. Cancer 1998;62:2152-65.
10. Coons SW, Pearl DK. Mitosis identification in diffuse gliomas: implications for tumor grading. Cancer 1998;82:1550-5. (Pubitemid 28165002)
11. Kleihues P, Davis RL, Coons SW, et al. Anaplastic astrocytoma. In: Kleihuis P, Cavenee WK, eds. Pathology and genetics of tumors of the nervous system. 2nd ed. Lyon: International Agency for Research, 2000;27-28.
12. Giannini C, Scheithauer BW, Burger PC, et al. Cellular proliferation in pilocytic and diffuse astrocytomas. J Neuropathol Exp Neurol 1999;58:46-53. (Pubitemid 29053025)
13. Brat DJ, Van Meir EG. Glomeruloid microvascular proliferation orchestrated by VPF/VEGF: a new world of angiogenesis research. Am J Pathol 2001;158:789-96. (Pubitemid 32221771)
14. Wesseling P, Schlingemann RO, Rietveld FJ, et al. Early and extensive contribution of pericytes/vascular smooth muscle cells to microvascular proliferation in glioblastoma multiforme: an immuno-light and immuno-electron microscopic study. J Neuropathol Exp Neurol 1995;54:304-10.
15. Rojiani AM, Dorovini-Zis K. Glomeruloid vascular structures in glioblastoma multiforme: an immunohistochemical and ultrastructural study. J Neurosurg 1996;85:1078-84. (Pubitemid 26396562)
16. Barker FG II, Davis RL, Chang SM, et al. Necrosis as a prognostic factor in glioblastoma multiforme. Cancer 1996;77:1161-6. (Pubitemid 26080909)
17. Margetts JC, Kalyan-Raman UP. Giant-celled glioblastoma of brain. A clinico-pathologic and radiologic study of ten cases (including immunohistochemistry and ultrastructure). Cancer 1989;63:524-31. (Pubitemid 19038469)
18. Burger PC, Vollmer RT. Histologic factors of prognostic significance in the glioblastoma multiforme. Cancer 1980;46:1179-86. (Pubitemid 10043487)
19. Burger PC, Pearl DK, Aldape K, et al. Small cell architecture - a histologic equivalent of EGFR amplification in glioblastoma multiforme? J Neuropathol Exp Neurol 2001;60:1099-1104. (Pubitemid 33021443)
20. Meis JM, Martz KL, Nelson JS. Mixed glioblastoma multiforme and sarcoma. A clinicopathologic study of 26 radiation therapy group cases. Cancer 1991;67:2342-9.
21. Meis JM, Ho KL, Nelson JS. Gliosarcoma: a histologic and immunohistochemical reaffirmation. Mod Pathol 1990;3:19-24.
22. Watanabe K, Tachibana O, Yonekawa Y, et al. Role of gemistocytes in astrocytoma progression. Lab Invest 1997;76:277-84. (Pubitemid 27082071)
23. Geddes JF, Thom M, Robinson SF, et al. Granular cell change in astrocytic tumors. Am J Surg Pathol 1996;20:55-63. (Pubitemid 26007710)
24. Scherer HJ. Cerebral astrocytomas and their derivatives. Am J Cancer 1940;40:159-98.
25. von Deimling A, von Ammon K, Schoenfeld D, et al. Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 1993;3:19-26. (Pubitemid 23046372)
26. Kleihues P, Ohgaki H. Primary and secondary glioblastoma: from concept to clinical diagnosis. Neuro-Oncology 1999;1:44-51.
27. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-9. (Pubitemid 28482012)
28. Mason W, Louis DN, Cairncross JG. Chemosensitive gliomas in adults: which ones and why? J Clin Oncol 1997;15:3423-6. (Pubitemid 27527712)
29. Ekstrand AJ, James CD, Cavenee WK, et al. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 1991;51:2164-72.
30. Libermann TA, Nusbaum HR, Razon N, et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumors of glial origin. Nature 1985;313:144-7. (Pubitemid 15192341)
31. Lang FF, Miller DC, Koslow M, et al. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg 1994;81:427-36. (Pubitemid 24267651)
32. Wong AJ, Ruppert JM, Bigner SH, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 1992;89:2965-9.
33. Frederick L, Wang XY, Eley G, et al. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000;60:1383-7. (Pubitemid 30152011)
34. Fulci G, Ishii N, Van Meir EG. p53 and brain tumors: from gene mutations to gene therapy. Brain Pathol 1998;8:599-613. (Pubitemid 28460920)
35. Ishii N, Maier D, Merlo A, et al. Frequent coalterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 1999;9:469-79. (Pubitemid 29316287)
36. Van Meir EG, Kikuchi T, Tada M, et al. Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res 1994;54:649-52. (Pubitemid 24068319)
37. Albertoni M, Daub DM, Arden KC, et al. Genetic instability leads to loss of both p53 alleles in a human glioblastoma. Oncogene 1998;16:321-6. (Pubitemid 28052286)
38. Van Meir EG, Roemer K, Diserens AC, et al. Single cell monitoring of growth arrest and morphologic changes induced by transfer of wild-type p53 alleles to glioblastoma cells. Proc Natl Acad Sci USA 1995;92:1008-12.
39. Gratas C, Tohma Y, Van Meir EG, et al. Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol 1997;7:863-9. (Pubitemid 27346730)
40. Owen-Schaub LB, Zhang W, Cusack JC, et al. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 1995;15:3032-40.
41. Miyashita T, Krajewski S, Krajewska M, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994;9:1799-805. (Pubitemid 24163411)
42. Reifenberger G, Liu L, Ichimura K, et al. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993;53:2736-9. (Pubitemid 23180507)
43. Fulci G, Labuhn M, Maier D, et al. p53 gene mutation and ink4aarf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene 2000;19:3816-22. (Pubitemid 30621189)
44. Nakamura M, Watanabe T, Klangby U, et al. p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 2001;11:159-68. (Pubitemid 32198843)
45. Schmidt EE, Ichimura K, Reifenberger G, et al. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 1994;54:6321-4.
46. Nishikawa R, Furnari FB, Lin H, et al. Loss of p16INK4 expression is frequent in high grade gliomas. Cancer Res 1995;55:1941-5.
47. Costello JF, Plass C, Arap W, et al. Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Res 1997;57:1250-4. (Pubitemid 27152546)
48. Hayashi Y, Ueki K, Waha A, et al. Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol 1997;7:871-5. (Pubitemid 27346731)
49. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-7. (Pubitemid 27148818)
50. Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997;15:356-62. (Pubitemid 27147102)
51. Mollenhauer J, Wiemann S, Scheurlen W, et al. DMBT1, a new member of the SRCR superfamily on chromosome 10q25.3-26.1 is deleted in malignant brain tumors. Nat Genet 1997;17:32-9. (Pubitemid 27377529)
52. Nakamura H, Yoshida M, Tsuiki H, et al. Identification of a human homolog of the Drosophila neuralized gene within the 10q25.1 malignant astrocytoma deletion region. Oncogene 1998;16:1009-19. (Pubitemid 28107939)
53. Peraud A, Watanabe K, Schwechheimer K, et al. Genetic profile of the giant cell glioblastoma. Lab Invest 1999;79:123-9. (Pubitemid 29110643)
54. Meyer-Puttlitz B, Hayashi Y, Waha A, et al. Molecular genetic analysis of giant cell glioblastomas. Am J Pathol 1997;151:853-7. (Pubitemid 27385617)
55. Reis RM, Konu-Lebleblicioglu D, Lopes JM, et al. Genetic profile of gliosarcomas. Am J Pathol 2000;156:425-32. (Pubitemid 30643797)
56. Kleihues P, Burger PC, Collins VP, et al. Glioblastoma. In: Kleihues P, Cavenee WK, eds. Pathology and genetics of tumors of the nervous system. 2nd ed. Lyon: International Agency for Research on Cancer, 2000:88-9.
57. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
58. Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-8.
59. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
60. Kerbel RS. Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000;21:505-15. (Pubitemid 30137936)
61. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64. (Pubitemid 26272076)
62. Dvorak HF. VPF/VEGF and the angiogenic response. Semin Perinatol 2000;24:75-8. (Pubitemid 30115277)
63. Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-39.
64. Sundberg C, Nagy JA, Brown LF, et al. Glomeruloid microvascular proliferation follows adenoviral VPF/VEGF164 gene delivery. Am J Pathol 2001;158:1145-60.
65. Dvorak HF, Nagy JA, Feng D, et al. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 1999;237:97-132. (Pubitemid 28554861)
66. Ferrara N, Houck K, Jakeman L, et al. Molecular and biologic properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992;13:18-32.
67. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25. (Pubitemid 27076453)
68. Fukumura D, Xavier R, Sugiura T, et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998;94:715-25. (Pubitemid 28436004)
69. Fukumura D, Yuan F, Monsky WL, et al. Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. Am J Pathol 1997;151:679-88. (Pubitemid 27385599)
70. Eberhard A, Kahlert S, Goede V, et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000;60:1388-93. (Pubitemid 30152012)
71. Van Meir EG. Cytokines and tumors of the central nervous system. Glia 1995;15:264-88.
72. Desbaillets I, Diserens AC, de Tribolet N, et al. Regulation of interleukin-8 expression by reduced oxygen pressure in human glioblastoma. Oncogene 1999;18:1447-56. (Pubitemid 29103632)
73. Desbaillets I, Diserens AC, Tribolet N, et al. Upregulation of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis. J Exp Med 1997;186:1201-12. (Pubitemid 27469015)
74. Plate KH. Mechanisms of angiogenesis in the brain. J Neuropathol Exp Neurol 1999;58:313-20. (Pubitemid 29187893)
75. Plate KH, Breier G, Weich HA, et al. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-8.
76. Plate KH, Breier G, Weich HA, et al. Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 1994;59:520-9. (Pubitemid 24357278)
77. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1999;359:843-5.
78. Kung AL, Wang S, Klco JM, et al. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med 2000;6:1335-40. (Pubitemid 32001016)
79. Semenza GL, Agani F, Feldser D, et al. Hypoxia, HIF-1, and the pathophysiology of common human diseases. Adv Exp Med Biol 2000;475:123-30. (Pubitemid 32197719)
80. Takano S, Yoshii Y, Kondo S, et al. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res 1996;56:2185-90. (Pubitemid 26119923)
81. Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995;376:62-6.
82. Fong GH, Rossant J, Gertsenstein M, et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995;376:66-70.
83. Sato TN, Tozawa Y, Deutsch U, et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995;376:70-4.
84. Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 1999;18:5356-62. (Pubitemid 29462372)
85. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994-8. (Pubitemid 29309448)
86. Zagzag D, Hooper A, Friedlander DR, et al. In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis. Exp Neurol 1999;159:391-400. (Pubitemid 29485225)
87. Zagzag D, Amirnovin R, Greco MA, et al. Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis. Lab Invest 2000;80:837-49. (Pubitemid 30421801)
88. Ueba T, Nosaka T, Takahashi JA, et al. Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells. Proc Natl Acad Sci USA 1994;91:9009-13.
89. Takahashi JA, Mori H, Fukumoto M, et al. Gene expression of fibroblast growth factors in human gliomas and meningiomas: demonstration of cellular source of basic fibroblast growth factor mRNA and peptide in tumor tissues. Proc Natl Acad Sci USA 1990;87:5710-4.
90. Grossfeld GD, Ginsberg DA, Stein JP, et al. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst 1997;89:219-27. (Pubitemid 27073759)
91. Bouvet M, Ellis LM, Nishizaki M, et al. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression inhibits angiogenesis in human colon cancer. Cancer Res 1998;58:2288-92. (Pubitemid 28252680)
92. Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 2000;14:34-44. (Pubitemid 30051577)
93. Van Meir EG, Polverini PJ, Chazin VR, et al. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat Genet 1994;8:171-6. (Pubitemid 24308365)
94. Nishimori H, Shiratsuchi T, Urano T, et al. A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis. Oncogene 1997;15:2145-50. (Pubitemid 27493903)
95. Hsu SC, Volpert OV, Steck PA, et al. Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombo-spondin-1. Cancer Res 1996;56:5684-91. (Pubitemid 26422173)
96. Wen S, Stolarov J, Myers MP, et al. PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci USA 2001;98:4622-7. (Pubitemid 32295026)